Skip to NavigationSkip to content

UCB and Novartis expand alliance in Germany

Published on 01/09/09 at 02:31pm

UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug Provas.

The deal sees UCB extend its rights beyond 2011 for the German market to the drug, marketed elsewhere under the Diovan (valsartan) brand.

In addition, UCB has licensed in commercial rights for two line extensions: Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).

Dafiro HCT is the first drug for the treatment of hypertension with a combination of three compounds in about 20 years.

In addition, UCB will co-commercialise the two new oral anti-diabetics Jalra and Icandra (vildagliptin and vildagliptin + metformin).

"With this agreement we are building on our strengths in Germany, our excellent position in the Internal Medicine segment," said Willy Cnops, vice president UCB and managing director Germany.

"We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

UCB Germany is focused on the fields of central nervous system, immunology disorders and internal medicine, employing around 1,400 people. UCBs product range in Germany covers indications ranging from cardiovascular diseases to respiratory diseases through to vascular diseases

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches